Peroxisome proliferator-activated receptor-gamma (PPARγ) agonists—typified by the thiazolidinedione (TZD) class of oral anti-T2DM medications—have not lived up to original high expectations of being among the first non-oncological drugs to be repurposed as molecularly-targeted anticancer therapies. Here, PPARG is linked to type 2 diabetes mellitus.